We bring together established leaders in target discovery, cancer biology, functional genomics and translational medicine, united around the common goal of understanding and treating cancer in ways that have never been done.

Leadership Team

Barbara Weber, MD

Chief Executive Officer
Venture Partner, Third Rock Ventures

Barbara Weber is a Venture Partner at Third Rock Ventures and brings more than 25 years of experience in oncology R&D in senior leadership roles. Barbara focuses on the formation, development and strategy of Third Rock’s oncology portfolio companies. She was a senior member of the team that launched Relay Therapeutics in September 2016 and served as Interim CMO for Neon Therapeutics from launch to December 2016.

Prior to joining Third Rock, Barbara held the position of Senior Vice President and Global Head of Oncology Translational Medicine at Novartis from 2009 to 2015. Prior to joining Novartis, Barbara served as Vice President Oncology Discovery and Translational Medicine at GlaxoSmithKline from 2005 to 2009. Until 2005, Barbara was a Professor of Medicine and Genetics at The University of Pennsylvania School of Medicine, leading a clinical and translational research program in cancer genetics and the UPenn Cancer Center Breast Cancer program.

Barbara is a member of the honorary societies American Association of Physicians and the American Society for Clinical Investigation, of which she served as President in 2005. Barbara also has served on numerous scientific advisory boards and on the Board of Directors of both the American Society of Clinical Oncology and the American Association of Cancer Research. Barbara is a graduate of the University of Washington School of Medicine. She completed her residency in Internal Medicine at Yale University School of Medicine and her fellowship in Medical Oncology at the Dana-Farber Cancer Institute.

Cary Pfeffer, MD

Interim Chief Business Officer
Partner, Third Rock Ventures

Cary Pfeffer is a partner at Third Rock Ventures and the interim chief business officer of Tango Therapeutics. He joined Third Rock Ventures at its inception in 2007 and has more than 20 years of business development and transaction experience, along with a broad array of biotech product development experience. Cary leads Third Rock’s partner development efforts, including building and maintaining strong relationships to work with large biotech and pharmaceutical companies. He has played an instrumental role in a number of innovative alliances and collaborative company building efforts across Third Rock’s portfolio, including industry-leading global strategic collaborations between Agios and Celgene in the field of cancer metabolism, and Nurix and Celgene in the field of ubiquitin ligases. Cary supports and advises on business development efforts across Third Rock’s portfolio and also assumes active leadership roles in its portfolio companies, functioning as chief executive officer and chief business officer through the first 12-18 months after launch. Cary was the interim chief business officer of Eleven Biotherapeutics, interim CEO of Jounce Therapeutics and Neon Therapeutics, and currently serves as a board member for Ablexis, Edimer, and Jounce Therapeutics.

Before joining Third Rock, Cary founded The Pfeffer Group, a boutique consulting firm that provided business development and strategy advisory services, completing multiple transactions for leading biotechnology and life sciences companies. Prior to that, Cary spent more than a decade at Biogen, where he held a variety of senior and executive level U.S. and global management roles focused on business and market development, product development and commercial operations. Earlier in his career, Cary spent several years in corporate finance in the health care investment banking group of Lehman Brothers.

Cary earned his doctor of medicine from the University of Pennsylvania, his Master of Business Administration from the Wharton School of the University of Pennsylvania and holds a Bachelor of Arts in biochemistry from Columbia University.

Daniella Beckman, CPA

Chief Financial Officer

Daniella Beckman is the part-time chief financial officer of Tango Therapeutics where she leads the finance functions and strategic financial planning. She is also the part-time chief financial officer of Neon Therapeutics. Prior to Tango and Neon, she was the chief financial officer of Idenix Pharmaceuticals until it was acquired by Merck in 2014. At Idenix, she oversaw accounting, finance, treasury, investor relations, IT and equity raises. Daniella also served as Idenix’s corporate controller. Earlier in her career, Daniella held various finance positions at Coley Pharmaceuticals, Biogen Idec and PricewaterhouseCoopers.

Daniella holds a Bachelor of Arts in business administration/accounting from Boston University. She is also a certified public accountant in Massachusetts.

Alan Huang, PhD

SVP, Head of Biology

Alan Huang joined Tango Therapeutics as senior vice president, head of biology, after serving as a consultant at Third Rock Ventures, where he played a leading role in the creation and launch of Tango. Alan brings over 15 years of experience in oncology translational research, target discovery and drug development, most recently from Novartis Institute for Biomedical Research as senior director and interim global head of oncology translational research. In this role, Alan was responsible for generating trial enabling pre-clinical concepts to aid patient selection, biomarker, and combination strategies and worked alongside the clinical teams to implement and execute. Under his leadership, the group advanced many key Novartis pipeline compounds, including PI3K inhibitors BYL719 and BKM120, mTOR inhibitor Everolimus, cMET inhibitor INC280 and ALK inhibitor Ceritinib through development and registration. Prior to this, Alan was responsible for a variety of drug discovery and target ID platforms in oncology research. Most notably, he pioneered the pooled based shRNA screening technology. Prior to joining Novartis, Alan worked at Millennium Pharmaceuticals as senior scientist focusing on the discovery of novel targets to treat metabolic diseases.

Alan obtained his Bachelor of Science in biochemistry from Fudan University and his doctorate in biochemistry & molecular biology from the University of South Alabama. He completed a postdoctoral fellowship at Schepen’s Eye Research Institute of Harvard Medical School, studying the role of BCL2 in CNS axonal regeneration. Alan is an author on over 30 peer reviewed publications and an inventor of nearly 20 patents.

Janid Ali, PhD

VP, Biochemistry

Janid Ali oversees biochemistry at Tango Therapeutics, leading an internal group and external CRO efforts to discover and develop drugs for novel oncology targets. Janid brings over 17 years of drug discovery experience, with a successful track record of initiating early drug discovery programs and advancing them into the clinic.

Prior to Tango Therapeutics, Janid spent 13.5 years at Infinity Pharmaceuticals, with increasing roles and responsibilities, focusing on the development of new oncology and analgesic agents. Janid built and led the Infinity biochemistry group, which was involved in and a key contributor to all early discovery projects, resulting in 4 compounds entering clinical trials targeting Hsp90, FAAH and PI3K. Prior to Infinity, Janid built and led the biochemistry group at Essential Therapeutics, aimed at discovering new antibiotics.

Janid earned his Bachelor of Science in biochemistry at the University of East Anglia U.K, and his doctorate studying the energy coupling mechanism of DNA gyrase in the lab of Anthony Maxwell at the University of Leicester, U.K. His postdoctoral research focused on the unwinding mechanism of UvrD helicase, utilizing pre-steady state enzyme kinetics, at Washington University School of Medicine, and was completed in the department of biochemistry and molecular biophysics in the lab of Tim Lohman.

Tania Philipp

VP, Human Resources

Tania Philipp is VP, Human Resources at Tango Therapeutics, and has led human resources management teams at life sciences companies for over 15 years. Prior to joining Tango, she served as the executive director, global human resources for Bavarian Nordic, where she was responsible for global HR for over 400 employees worldwide. Specifically, Tania oversaw talent acquisition, leadership development, organizational design, and global total compensation and benefits programs. Prior to Bavarian Nordic, Tania served as director, human resources for Mendel Biotechnology, an agricultural biotechnology company acquired by Koch Industries, and held various senior human resources positions at Sunesis Pharmaceuticals, Pearl Therapeutics (acquired by AstraZeneca) and Protein Design Labs. Tania received her M.A. in behavioral psychology from the University of the Pacific.

John Maxwell, PhD

VP, Medicinal Chemistry

John Maxwell joins Tango Therapeutics from Vertex Pharmaceuticals where he spent 15 years in roles of increasing responsibility in the Medicinal Chemistry group. Most recently, John led a group with primary responsibilities for projects in early research, lead generation, and lead optimization. He has worked in a variety of therapeutic areas, and took on the role of chemistry head in infectious disease and oncology projects and research project leader in oncology and respiratory disease projects. His teams have delivered clinical candidates on projects including Hepatitis C protease and DNA-PK for oncology.

John received his doctorate in chemistry from Johns Hopkins University and obtained a Bachelor of Science. in chemistry from St. Joseph’s University.

Dimitris Papoutsakis, PHD

VP, Operations, Program and Portfolio Management

Dimitris Papoutsakis oversees operations, program and portfolio management at Tango Therapeutics. Dimitris brings over 16 years of drug development experience across several therapeutic areas. He joins Tango Therapeutics from Novartis Oncology, where he was senior director in oncology business development and licensing overseeing alliances with biotech and pharmaceutical companies. Dimitris has also held roles at the Novartis Institute for Biomedical Research in chemical development, pharmaceutical development, technical project management, and oncology program management, where he was the Cambridge site head of the group.

Dimitris obtained his Bachelor of Science in Chemistry from the University of Crete in Greece, his doctorate in chemistry from Michigan State University, and completed a postdoctoral fellowship at Massachusetts Institute of Technology.

Alan Ashworth, PhD, FRS

President of the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

Alan Ashworth is president, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center; senior vice president for cancer services, UCSF Health; a professor of medicine, division of hematology / oncology, department of medicine; and E. Dixon Heise Distinguished Professor in Oncology. He took up this appointment in January 2015. Previously, he was CEO of the Institute of Cancer Research in London, U.K.

One of Alan’s major contributions to cancer research has been his work on genes involved in cancer susceptibility. He was a key part of the team that in 1995 discovered the gene BRCA2, which is linked to an increased risk of some types of cancers. Ten years later, Alan identified a way to exploit genetic weaknesses in cancer cells including mutated BRCA1 and BRCA2, leading to a new synthetic lethal approach to cancer treatment, which is now approved for clinical use. His current research focuses on leveraging basic biology into personalized cancer medicines.

Alan is an elected member of EMBO, a Fellow of the Academy of Medical Sciences and a Fellow of the Royal Society. He has been the recipient of a number of scientific prizes and awards, including The European Society of Medical Oncology Lifetime Achievement Award, the David T. Workman Memorial Award of the Samuel Waxman Cancer Research Foundation, the Meyenburg Foundation’s Cancer Research Award, the Basser Global Prize and the Genetics Society Medal.

José Baselga, MD, PhD

Physician-in-Chief at Memorial Sloan Kettering Cancer Center

José Baselga is the physician-in-chief at Memorial Sloan Kettering Cancer Center (MSK) and professor of medicine at Weill Cornell Medical College. His longstanding research interests are in the development of targeted agents for the treatment of breast cancer and in studying strategies to overcome mechanisms of resistance, with over 457 peer-reviewed publications to date. He conducted pivotal laboratory and clinical studies that led to the approval of trastuzumab, pertuzumab and everolimus, among other therapies. His current work is in targeting PI3K and deciphering mechanisms of resistance to anti-estrogen therapies.

Prior to MSK, José was the chief of the division of hematology / oncology, associate director of the Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School. He was also the chairman of medical oncology and founding director of the Vall d’Hebron Institute of Oncology in Barcelona, Spain. José is a past president of the American Association of Cancer Research (AACR), a past president of the European Society for Medical Oncology (ESMO) and a past member of the board of directors for the American Society of Clinical Oncology. He is an elected member of the National Academy of Medicine, the American Society of Clinical Investigation, the Association of American Physicians and a Fellow of the AACR Academy. He is a past member of the editorial boards of Cancer Cell, Journal of Clinical Oncology and Clinical Cancer Research and is the founding editor-in-chief for the AACR flagship journal, Cancer Discovery.

Levi Garraway, MD, PhD

Senior Vice President, Global Development and Medical Affairs, Eli Lilly and Company

Levi Garraway, M.D., Ph.D., joined Eli Lilly and Company in January 2017 and is currently senior vice president, global development and medical affairs.

Levi received his A.B., doctor of medicine and doctor of philosophy from Harvard Medical School. Thereafter, he did an internship and residency in internal medicine at the Massachusetts General Hospital, where he also served as medical chief resident in 2003. Levi completed his fellowship training in medical oncology at the Dana-Farber Cancer Institute. He received board certification in internal medicine and medical oncology.

Prior to joining Lilly, Levi served as an investigator of the Howard Hughes Medical Institute and an associate professor of medicine at the Dana-Farber Cancer Institute, Harvard Medical School and an Institute Member of the Broad Institute. He was the inaugural director of the Joint Center for Cancer Precision Medicine, which spans the Dana-Farber, Brigham and Women's Hospital, Boston Children's Hospital and the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard. Levi led a research group that studied cancer genomics, drug resistance and cancer precision medicine. His research informed several gene targets and “druggable” pathways relevant to the genesis and therapeutic vulnerabilities of melanoma, prostate cancer and other malignancies. His group developed a platform for systematic cancer mutation profiling that inspired multiple personalized cancer medicine efforts across the U.S. and beyond. Levi serves on the scientific advisory boards of major cancer centers, including Sloan Kettering and MD Anderson, and he is a member of several major National Institutes of Health (NIH) and National Cancer Institute (NCI) advisory committees.

Levi has received numerous awards, including the Paul Marks Prize for Cancer Research, the Jane Cooke Wright Award from the American Association of Cancer Research (AACR), the New Innovator Award from the NIH and an Outstanding Investigator Award from the National Cancer Institute. In 2009, Levi was inducted into the American Society for Clinical Investigation and served as president of this society in 2015-16. In 2015 he was inducted into the Association for American Physicians

William G. Kaelin, Jr., MD

Professor in the Department of Medicine at the Dana-Farber Cancer Institute, Harvard Medical School and a Howard Hughes Medical Institute Investigator

William Kaelin is a professor in the department of medicine at the Dana-Farber Cancer Institute and at the Brigham and Women's Hospital, Harvard Medical School. A Howard Hughes Medical Institute investigator since 1998, William’s research seeks to understand how, mechanistically, mutations affecting tumor-suppressor genes such as VHL, RB1 and p53 cause cancer. His long-term goal is to lay the foundation for new anticancer therapies based on the biochemical functions of such proteins. His work on the VHL protein helped to motivate the successful clinical testing of VEGF inhibitors for the treatment of kidney cancer as well ongoing trials of a HIF2 inhibitor for this disease. In addition, this line of investigation led to ongoing clinical trials of drugs that stabilize HIF2 for the treatment of anemia.

William is a member of the National Academy of Sciences, National Academy of Medicine, the American Society of Clinical Investigation and the American College of Physicians. He recently served on the National Cancer Institute’s board of scientific advisors, the American Association of Cancer Research’s (AACR) board of trustees and the Institute of Medicine National Cancer Policy Board. He is a recipient of numerous awards, including the Albert Lasker Basic Medical Research Award, which he received in 2016.

William obtained his undergraduate degree and doctor of medicine from Duke University and completed his training in internal medicine at the Johns Hopkins Hospital, where he served as chief medical resident. He was a clinical fellow in medical oncology at the Dana-Farber Cancer Institute and later a postdoctoral fellow and McDonnell Scholar in David Livingston’s laboratory.

Timothy K. Lu, MD, PhD

Associate Professor of Biological Engineering, Electrical Engineering and Computer Science at the Massachusetts Institute of Technology

Timothy Lu is an associate professor leading the synthetic biology group in the department of electrical engineering and computer science and the department of biological engineering at Massachusetts Institute of Technology (MIT). Tim graduated with his S.B. and master’s degree in engineering from MIT, and his doctor of medicine / doctor of philosophy from the Harvard-MIT Health Sciences and Technology Program. He is a core member of the MIT Synthetic Biology Center and a cofounder of multiple biotechnology companies innovating new diagnostic and therapeutic technologies for human health.

Tim’s research at MIT focuses on establishing powerful synthetic biology technologies for cell engineering as well as high-throughput approaches for mapping genetic networks involved in disease pathogenesis. He is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the National Institutes of Health (NIH) New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, among others.

Antoni Ribas, MD, PhD

Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles

Antoni Ribas is professor of medicine, professor of surgery, and professor of molecular and medical pharmacology at the University of California Los Angeles (UCLA); director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC); director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA; and chair of the Melanoma Committee at SWOG. Antoni is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA. His National Cancer Institute (NCI), state of California and private foundation-supported research laboratory develops models of disease to test new therapeutic options and studies mechanism of action of treatments in patients and the molecular mechanisms of therapy resistance. He is an elected member of the American Society of Clinical Investigation (ASCI), and has been the recipient of the AACR Richard and Hinda Rosenthal Award and an NCI Outstanding Investigator Award.

Alexis Borisy

Chairman of Tango Therapeutics and Partner, Third Rock Ventures

Alexis Borisy is a partner at Third Rock Ventures and chairman of Tango Therapeutics’ board of directors. He is a successful biotechnology entrepreneur with more than 20 years of experience building and operating innovative science-based organizations. Alexis joined Third Rock Ventures in 2009 to focus on the formation, development and strategy of new companies. He has played key roles in launching and building several of Third Rock’s portfolio companies. He was the chairman of the board, co-founder, and interim CEO of Foundation Medicine, interim CEO of Warp Drive and Blueprint Medicines, and currently serves as a board member of Foundation Medicine, Warp Drive Bio, Blueprint Medicines, Editas Medicine, and Revolution Medicine.

Prior to joining Third Rock Ventures, Alexis founded CombinatoRx in 2000, serving as its chief executive officer and bringing the company public on the NASDAQ. He has raised billions in financing and business development deals, and has authored numerous scientific papers and patents. Trained in chemistry and chemical biology at Harvard where he was a Howard Hughes Predoctoral Fellow, Alexis was honored as the Massachusetts Institute of Technology’s Technology Review Innovator of the Year. He was also chosen as the New England Entrepreneur of the Year in Life Sciences and was honored as a Presidential Scholar.

Alexis’ undergraduate degree in chemistry is from the University of Chicago, and he did his graduate work in the laboratory of Dr. Stuart Schreiber at Harvard University. Alexis is a trustee of the Boston Museum of Science, is a co-founder and former chairman of FORMA Therapeutics, and serves on the board of the National Venture Capital Association.

Michael Pellini, MD

Board Member

Michael Pellini joined Foundation Medicine as president and chief executive officer in May 2011 and transitioned to chairman in February 2017. As a physician with more than 20 years of operating experience with companies at the forefront of the clinical diagnostics and laboratory industries, Michael brings a breadth of understanding in personalized medicine, with a particular interest and focus in oncology. He currently serves as a member of the board of directors for Mass BIO and the Personalized Medicine Coalition, in addition to his board chair position with Foundation Medicine. Michael is a member of the President’s Leadership Council for the Sydney Kimmel Medical School at Thomas Jefferson University.

Allen Oliff, MD

Senior Vice President, Research & Development GSK

Allen Oliff, MD is senior vice president, research & development at GSK and brings more than three decades of experience in oncology R&D to the Tango Therapeutics Board of Directors. Allen joined GSK in May 2001 and has held leadership positions of increasing responsibility within research & development, specifically the Center of Excellence for Drug Discovery and the Molecular Discovery Research Department. During his career at GSK he has led the creation of seven marketed products and two other agents that are in late stage development, including drugs used to treat various forms of cancer. He also established GSK’s Virtual Proof of Concept (VPoC) Discovery Performance Unit. Before that, he held leadership positions at DuPont Pharmaceuticals and Merck and Co., where he was Executive Director of Cancer Research.

Allen began his career in oncology research, serving in multiple roles at Memorial Sloan Kettering Cancer Center before being promoted to associate member. He was also an associate professor in the Cornell University Graduate School of Medical Sciences, Sloan Kettering Division. During his research career he investigated the molecular pathogenesis of cancer with a focus on RNA tumor viruses, oncogenes, and tumor suppressor genes. He has authored over 120 peer-reviewed publications on these topics.

Allen is a board-certified internist and medical oncologist and a member of the American Society of Clinical Investigation, the Harvey Society, the American Association for Cancer Research, the American Society of Hematology, the American Society of Clinical Pharmacology and Therapeutics, and the American Society of Clinical Oncology. He earned his undergraduate degree from Brandeis University and his doctor of medicine from the Albert Einstein College of Medicine. He completed his training in internal medicine at the Bronx Municipal Hospital Center in New York and his fellowship training in medical oncology in the Clinical Oncology Program of the National Cancer Institute at the National Institutes of Health in Bethesda, MD. He completed his post-doctoral training in molecular genetics and tumor virology in the laboratory of Dr. Edward Scolnick.